SML3085

Evacetrapib

≥95% (HPLC)

• 别名: LY 2484595, LY-2484595, LY2484595, trans-4-({(5S)-5-[{[3,5-bis(Trifluoromethyl)phenyl]methyl}(2-methyl-2H-tetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzazepin-1-yl}methyl)cyclohexanecarboxylic acid, trans-4-[[(5S)-5-[[[3,5-bis(Trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
• 经验公式（希尔记法）: C₃₁H₃₆F₆N₆O₂
• CAS号: 1186486-62-3
• 分子量: 638.65
• MDL號碼: MFCD23105886
• 分類程式碼代碼: 51111800
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥95% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: −20°C
• SMILES 字串: CC1=C2C([C@@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C4=NN(C)N=N4)CCCN2C[C@H]5CC[C@H](C(O)=O)CC5)=CC(C)=C1
• InChI: 1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
• InChI 密鑰: IHIUGIVXARLYHP-UXNJHFGPSA-N

说明

生化／生理作用

Evacetrapib (LY2484595) is an orally active, potent and selective cholesteryl ester transfer protein (CETP) inhibitor (human recombinant CETP IC50 = 5.5 nM). Evacetrapib inhibits CETP activtiy in human plasma ex vivo (IC50 = 36 nM) and in human CETP/ApoAI transgenic mice in vivo (129.7% HDL-C increase 8 h post oral dosing at 30 mg/kg; 98.4%, 98.6%, 18.4% CETP inhibition, respectivley, post 4, 8 and 24 h p.o.). Evacetrapib does not cause the side-effects observed with torcetrapib in cultures (no aldosterone or cortisol synthesis induction in H295R cells) or in vivo (no increase of mean arterial pressure in diabetic fatty rats).

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable